NEW YORK (GenomeWeb) – Affymetrix and UK-based XRGenomics are collaborating on the development of new diagnostic tests for neurodegenerative diseases, the companies said today.

Financial and other terms of the agreement were not disclosed.

XRGenomics has used Affymetrix's GeneTitan microarray technology to develop gene expression signatures and find biomarkers for diseases such as Alzheimer's disease.

The firm plans to use the technology to optimize its RNA signatures in large clinical trials involving thousands of patients with cognitive impairment.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.